MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Bought by Nuveen Asset Management LLC

Nuveen Asset Management LLC increased its stake in shares of MeiraGTx Holdings plc (NASDAQ:MGTX - Free Report) by 43.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 191,311 shares of the company's stock after acquiring an additional 57,737 shares during the quarter. Nuveen Asset Management LLC owned about 0.24% of MeiraGTx worth $1,165,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its stake in MeiraGTx by 68.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,975 shares of the company's stock worth $30,000 after acquiring an additional 2,016 shares in the last quarter. Corebridge Financial Inc. raised its stake in MeiraGTx by 11.6% during the 4th quarter. Corebridge Financial Inc. now owns 23,147 shares of the company's stock worth $141,000 after acquiring an additional 2,405 shares in the last quarter. Summit Investment Advisors Inc. increased its stake in MeiraGTx by 106.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,871 shares of the company's stock valued at $30,000 after purchasing an additional 2,515 shares during the period. SG Americas Securities LLC increased its stake in MeiraGTx by 13.3% in the fourth quarter. SG Americas Securities LLC now owns 22,240 shares of the company's stock valued at $135,000 after purchasing an additional 2,617 shares during the period. Finally, Fort Sheridan Advisors LLC increased its stake in MeiraGTx by 7.0% in the fourth quarter. Fort Sheridan Advisors LLC now owns 69,955 shares of the company's stock valued at $426,000 after purchasing an additional 4,557 shares during the period. 67.48% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at MeiraGTx

In related news, CFO Richard Giroux sold 24,000 shares of the company's stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $6.00, for a total transaction of $144,000.00. Following the completion of the transaction, the chief financial officer now owns 882,494 shares of the company's stock, valued at approximately $5,294,964. This represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Alexandria Forbes sold 47,500 shares of the company's stock in a transaction that occurred on Tuesday, April 8th. The stock was sold at an average price of $5.34, for a total transaction of $253,650.00. Following the transaction, the chief executive officer now directly owns 1,408,983 shares of the company's stock, valued at $7,523,969.22. This trade represents a 3.26% decrease in their position. The disclosure for this sale can be found here. Insiders own 7.50% of the company's stock.

MeiraGTx Price Performance

Shares of NASDAQ MGTX traded up $0.52 on Friday, hitting $6.00. The company's stock had a trading volume of 436,494 shares, compared to its average volume of 372,445. MeiraGTx Holdings plc has a 12-month low of $3.85 and a 12-month high of $8.75. The company has a market capitalization of $482.19 million, a price-to-earnings ratio of -4.96, a price-to-earnings-growth ratio of 0.37 and a beta of 1.16. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.34 and a quick ratio of 2.34. The stock has a 50 day moving average of $5.67 and a 200-day moving average of $6.24.

MeiraGTx (NASDAQ:MGTX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.13). The firm had revenue of $1.93 million for the quarter, compared to analysts' expectations of $4.44 million. MeiraGTx had a negative net margin of 633.05% and a negative return on equity of 146.38%. As a group, research analysts predict that MeiraGTx Holdings plc will post -1.48 EPS for the current year.

Analysts Set New Price Targets

MGTX has been the topic of a number of recent research reports. Wall Street Zen lowered shares of MeiraGTx from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Royal Bank of Canada lifted their price objective on shares of MeiraGTx from $11.00 to $13.00 and gave the company an "outperform" rating in a research note on Monday, March 17th. Finally, Chardan Capital dropped their price objective on shares of MeiraGTx from $38.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th.

MeiraGTx Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.